	HIGHLIGHTS OF PRESCRIBING		FULL PRESCRIBING INFORMATION	<u>Intestinal Angioedema</u> Intestinal angioedema has occurred in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. In some cases, the angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor.		
	INFORMATION These highlights do not include all the information needed to use ZESTRIL safely		WARNING: FETAL TOXICITY • When pregnancy is detected, discontinue ZESTRIL as soon as possible <i>[see Warnings and Precautions (5.1)]</i> . • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus <i>[see</i>			
	and effectively. See full prescribing information for ZESTRIL.	WARNINGS AND PRECAUTIONS Angioedema: Discontinue Zestril, provide	Warnings and Precautions (5.1)].	Anaphylactoid Reactions	·	
	ZESTRIL® (lisinopril) tablets, for oral use	appropriate therapy and monitor until	1 INDICATIONS AND USAGE 1.1 Hypertension	<u>Anaphylactoid Reactions During Desensitization</u> Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained		
	Initial U.S. Approval: 1988	resolved (5.2)Renal impairment: Monitor renal function	Zestril is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and	life-threatening anaphylactoid reactions. Anaphylactoid Reactions During Dialysis		
	WARNING: FETAL TOXICITY	periodically (5.3)Hypotension: Patients with other heart	myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes.	Sudden and potentially life threatening a membranes and treated concomitantly v		
	See full prescribing information for complete boxed warning.	or renal diseases have increased risk,	Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate,	and aggressive therapy for anaphylactoid in these situations. In these patients, co	reactions must be initiated. Symptoms	nave not been relieved by antihistamines
	 •When pregnancy is detected, discontinue Zestril as soon as possible. (5.1) •Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1) 	 monitor blood pressure after initiation (5.4) Hyperkalemia: Monitor serum potassium periodically (5.5) Cholestatic jaundice and hepatic failure: Monitor for jaundice or signs of liver failure (5.6) 	Ipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on	a different class of antihypertensive age low-density lipoprotein apheresis with de	ent. Anaphylactoid reactions have also	
			Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).	5.3 Impaired Renal Function Monitor renal function periodically in patients treated with Zestril. Changes in renal function including acute renal failure		
			Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but	can be caused by drugs that inhibit the renin-angiotensin system. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, post-myocardial infarction or volume depletion) may be at particular risk of developing acute renal failure on Zestril. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on Zestril [see Adverse Reactions (6.1), Drug Interactions (7.4)].		
			reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.			
	INDICATIONS AND USAGE	ADVERSE REACTIONS	Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the	5.4 Hypotension Zestril can cause symptomatic hypotension, sometimes complicated by oliguria, progressive azotemia, acute renal failure		
	 Zestril is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older 	 Common adverse reactions (events 2% greater than placebo) by use: Hypertension: headache, dizziness and cough (6.1) Heart Failure: hypotension and chest pain 	absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower	or death. Patients at risk of excessive hypotension include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or salt depletion of any etiology. In these patients, Zestril should be started under very close medical supervision and such patients should be followed		
			blood pressure goal.			
			Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney			
	(1.1)Adjunct therapy for heart failure (1.2)	(6.1)Acute Myocardial Infarction: hypotension	disease). These considerations may guide selection of therapy. Zestril may be administered alone or with other antihypertensive agents <i>[see Clinical Studies (14.1)].</i>			
	 Treatment of Acute Myocardial Infarction (1.3) 	(6.1)	1.2 Heart Failure Zestril is indicated to reduce signs and symptoms of systolic heart failure [see Clinical Studies (14.2)].	Surgery/Anesthesia In patients undergoing major surgery or during anesthesia with agents that produce hypotension. Zestril may block		
BX OUIY PKG02654 Bev. 03/2020	DOSAGE AND ADMINISTRATION	To report SUSPECTED ADVERSE	1.3 Reduction of Mortality in Acute Myocardial Infarction	angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to		
(lisinopril) Tablets	 Hypertension: Initial adult dose is 10 mg 	REACTIONS, contact Almatica Pharma LLC at 877-447-7979 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.	Zestril is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction. Patients should receive, as appropriate, the standard recommended treatments such as	Serum potassium should be monitored periodically in patients receiving Zestril. Drugs that inhibit the renin angiotensin system can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing art to the development of the concomitant use of potassium-sparing diuretics.		
[®] lintseX	once daily. Titrate up to 40 mg daily based on blood pressure response.		thrombolytics, aspirin and beta-blockers [see Clinical Studies (14.3)]. 2 DOSAGE AND ADMINISTRATION			
	Initiate patients on diuretics at 5 mg once	DRUG INTERACTIONS	2.1 Hypertension Initial Therapy in adults: The recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood			
	daily (2.1) • Pediatric patients with glomerular	 Diuretics: Excessive drop in blood pressure (7.1) 	pressure response. The usual dosage range is 20 mg to 40 mg per day administered in a single daily dose. Doses up to 80 mg have been used but do not appear to give greater effect.	5.6 Hepatic Failure ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis and sometimes death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical treatment.		
	filtration rate > 30 mL/min/1.73m ² : Initial dose in patients 6 years of age	NSAIDS: Increased risk of renal	Use with diuretics in adults			
	and older is 0.07 mg per kg (up to	impairment and loss of antihypertensive efficacy (7.3)	If blood pressure is not controlled with Zestril alone, a low dose of a diuretic may be added (e.g., hydrochlorothiazide, 12.5 mg). After the addition of a diuretic, it may be possible to reduce the dose of Zestril.			
	5 mg total) once daily (2.1) • Heart Failure: Initiate with 5 mg once	• Dual inhibition of the renin-	The recommended starting dose in adult patients with hypertension taking diuretics is 5 mg once per day. Pediatric Patients 6 years of age and older with hypertension	6 ADVERSE REACTIONS 6.1 Clinical Trials Experience		
	daily. Increase dose as tolerated to 40 mg	angiotensin system: Increased risk of renal impairment, hypotension and	For pediatric patients with glomerular filtration rate > 30 mL/min/1.73m ² , the recommended starting dose is 0.07 mg per kg once daily (up to 5 mg total). Dosage should be adjusted according to blood pressure response up to a maximum of	Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed		
	 daily (2.2) Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI. Followed by 5 mg after 24 hours, then 10 mg once 	hyperkalemia (7.4)	0.61 mg per kg (up to 4 mg) not adjy. Dosag above 0.61 mg per kg (or in excess of 40 mg) have not been studied in pediatric patients [see Clinical Pharmacology (12.3)].	in practice. <u>Hypertension</u>		
Zestril® (lisinopril)			Zestril is not recommended in pediatric patients < 6 years or in pediatric patients with glomerular filtration rate	In clinical trials in patients with hypertension treated with Zestril, 5.7% of patients on Zestril discontinued with adverse reactions.		
Tablets	daily (2.3)		< 30 mL/min/1.73m ² [see Use in Specific Populations (8.4) and Clinical Studies (14.1)]. 2.2 Heart Failure	The following adverse reactions (events 2% greater on Zestril than on placebo) were observed with Zestril alone: headache (by 3.8%), dizziness (by 3.5%), cough (by 2.5%).		
PKG02654 Rev. 03/2020 Rx only	• Renal Impairment: For patients with creatinine clearance ≥ 10 mL/min and	 Concomitant mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7, 7.8) USE IN SPECIFIC POPULATIONS 	The recommended starting dose for Zestril, when used with diuretics and (usually) digitalis as adjunctive therapy for systolic heart failure, is 5 mg once daily. The recommended starting dose in these patients with hyponatremia (serum	Heart Failure	y 2.370).	
	≤ 30 mL/min, halve usual initial dose. For patients with creatinine clearance < 10 mL/min or on hemodialysis, the		sodium < 130 mEq/L) is 2.5 mg once daily. Increase as tolerated to a maximum of 40 mg once daily. Diuretic dose may need to be adjusted to help minimize hypovolemia, which may contribute to hypotension <i>[see Warnings</i>	The following adverse reactions (events 2% greater on Zestril than on placebo for 12 weeks. The following adverse reactions (events 2% greater on Zestril than on placebo) were observed with Zestril: hypotension (by 3.8%), chest pain (by 2.1%). In the two-dose ATLAS trial <i>[see Clinical Studies (14.2)]</i> in heart failure patients, withdrawals due to adverse reactions were not different between the low and high groups, either in total number of discontinuation (17% to 18%) or in rare specific reactions (< 1%). The following adverse reactions, mostly related to ACE inhibition, were reported more commonly in the high dose group:		
			and Precautions (5.4), and Drug Interactions (7.1)]. The appearance of hypotension after the initial does of Zestril does not preclude subsequent careful does litration with the drug, following effective management of the hypotension.			
	recommended initial dose is 2.5 mg (2.4)	Lactation: Advise not to breastfeed. (8.2) Page: Laga antibupartansiva affect in	2.3 Reduction of Mortality in Acute Myocardial Infarction			
	DOSAGE FORMS AND STRENGTHS Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg,	 Race: Less antihypertensive effect in blacks than non blacks (8.6) 	In hemodynamically stable patients within 24 hours of the onset of symptoms of acute myocardial infarction, give Zestril 5 mg orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily. Dosing should continue for at least six weeks.			
	40 mg (3)	See 17 for PATIENT COUNSELING	Initiate therapy with 2.5 mg in patients with a low systolic blood pressure (< 120 mmHg and > 100 mmHg) during the first			
	CONTRAINDICATIONS Angioedema or a history of hereditary or idiopathic angioedema (4)	INFORMATION Revised: 03/2020	3 days after the infarct <i>[see Warnings and Precautions (5.4)]</i> . If hypotension occurs (systolic blood pressure \leq 100 mmHg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension	Table 1 Dose-related Adverse Drug Read	tions: ATLAS trial	
			occurs (systolic blood pressure < 90 mmHg for more than 1 hour) Zestril should be withdrawn.		High Dose (n=1568)	Low Dose (n=1596)
			No dose adjustment of Zestril is required in patients with creatinine clearance > 30 mL/min. In patients with creatinine clearance \ge 10 mL/min and \le 30 mL/min, reduce the initial dose of Zestril to half of the usual recommended dose	Dizziness	19%	12%
	FULL PRESCRIBING INFORMATION: CONTENTS*	 7.4 Dual Blockade of the Renin- Angiotensin System (RAS) 7.5 Lithium 7.6 Codd 	i.e., hypertension, 5 mg; systolic heart failure, 2.5 mg and acute MI, 2.5 mg. Up titrate as tolerated to a maximum of 40 mg daily. For patients on hemodialysis or creatinine clearance < 10 mL/min, the recommended initial dose is 2.5 mg once daily	Hypotension Creatinine increased	11% 10%	7%
	WARNING: FETAL TOXICITY		[see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. 3 DOSAGE FORMS AND STRENGTHS	Hyperkalemia	6%	4%
	1 INDICATIONS AND USAGE 1.1 Hypertension	7.6 Gold 7.7 mTOR Inhibitors	2.5 mg are white, round, biconvex, uncoated tablets identified as "ZESTRIL 2 1/2" on one side and "135" on the other side. 5 mg are pink, capsule-shaped, biconvex, bisected, uncoated tablets identified as "ZESTRIL" on one side and "130" on	Syncope	7%	5%
	1.2 Heart Failure1.3 Reduction of Mortality in Acute	7.8 Neprilysin Inhibitor 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy	10 mg are pink, round, biconvex, uncoated tablets identified as "ZESTRIL 10" on one side and "131" on the other side. 20 mg are pale brownish red, round, biconvex, uncoated tablets identified as "ZESTRIL 10" on one side and "131" on the other side.	<u>Acute Myocardial Infarction</u> Patients treated with Zestril had a higher incidence of hypotension (by 5.3%) and renal dysfunction (by 1.3%) compared with patients not taking Zestril.		
	Myocardial Infarction 2 DOSAGE AND ADMINISTRATION	8.2 Lactation	other side.	Other clinical adverse reactions occurring in 1% or higher of patients with hypertension or heart failure treated with Zestril		
	2.1 Hypertension 8.4 Pediatric Use 2.2 Heart Failure 8.5 Geriatric Use		30 mg are pale brownish red, round, biconvex, uncoated tablets identified as "ZESTRIL 30" on one side and "133" on the other side.	in controlled clinical trials and do not appear in other sections of labeling are listed below: <u>Body as a whole:</u> Fatigue, asthenia, orthostatic effects.		
	2.3 Reduction of Mortality in Acute	 8.6 Race 8.7 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Hypertension 14.2 Heart Failure 14.3 Acute Myocardial Infarction 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION 	40 mg are yellow, round, biconvex, uncoated tablets identified as "ZESTRIL 40" on one side and "134" on the other side. 4 CONTRAINDICATIONS	<u>Digestive:</u> Pancreatitis, constipation, flatulence, dry mouth, diarrhea.		
	Myocardial Infarction 2.4 Dose in Patients with Renal		Zestril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Zestril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.2)].	<u>Hematologic:</u> Rare cases of bone marrow depression, hemolytic anemia, leukopenia/neutropenia and thrombocytopenia.		
	Impairment		Zestril is contraindicated in patients with:	Endocrine: Diabetes mellitus, inappropriate antidiuretic hormone secretion. Metabolic: Gout.		
	3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS		 a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor 	Skin: Urticaria, alopecia, photosensitivity, erythema, flushing, diaphoresis, cutaneous pseudolymphoma, toxic epidermal		
	5 WARNINGS AND PRECAUTIONS 5.1 Fetal Toxicity		 hereditary or idiopathic angioedema Do not co-administer aliskiren with ZESTRIL in patients with diabetes [see Drug Interactions (7.4)]. 	necrolysis, Stevens - Johnson syndrome, and pruritus. <u>Special Senses:</u> Visual loss, diplopia, blurred vision, tinnitus, photophobia, taste disturbances, olfactory disturbance.		
	5.2 Angioedema and Anaphylactoid		5 WARNINGS AND PRECAUTIONS 5.1 Fetal Toxicity	Urogenital: Impotence.		
	Reactions 5.3 Impaired Renal Function		Zestril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal	<u>Miscellaneous</u> : A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia, leukocytosis, paresthesia and vertigo. Rash, photosensitivity or other dermatological manifestations may occur alone or in combination with these symptoms. Clinical Laboratory Test Findings <u>Serum Potassium</u> : In clinical trials hyperkalemia (serum potassium greater than 5.7 mEq/L) occurred in 2.2% and 4.8% of Zestril-treated patients with hypertension and heart failure, respectively <i>[see Warnings and Precautions (5.5)]</i> .		
	5.4 Hypotension		system during the second and time timesters of pregnancy reduces tear renar indication and increases tear and neoratal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy			
	5.5 Hyperkalemia 5.6 Hepatic Failure		is detected, discontinue Zestril as soon as possible [see Use in specific Populations (8.1)].			
	6 ADVERSE REACTIONS 6.1 Clinical Trials Experience		5.2 Angioedema and Anaphylactoid Reactions Patients taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema. [see Drug Interactions (7.7, 7.8]].	Creatinine, Blood Urea Nitrogen: Minor increases in blood urea nitrogen and serum creatinine, reversible upon		
	6.2 Post-marketing Experience		Angioedema	discontinuation of therapy, were observed were more common in patients receiving and Proceedings (5.4). Beyogsible minor	concomitant diuretics and in patients v	vith renal artery stenosis [see Warnings

- 6.2 Post-marketing Experience 7 DRUG INTERACTIONS

- 7.1 Diuretics
 7.2 Antidiabetics
 7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors

Head and Neck Angioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx, including some fatal reactions, have occurred in patients treated with angiotensin converting enzyme inhibitors, including Zestril, at any time during treatment. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Zestril should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms of angioedema has occurred.

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the

full prescribing information are not listed.

discontinuation of therapy, were observed in about 2% of patients with hypertension treated with Zestri alone. Increases were more common in patients receiving concomitant diuretics and in patients with hypertension treated with Zestri alone. Increases and *Precautions (5.4)]*. Reversible minor increases in blood urea nitrogen and serum creatinine were observed in 11.6% of patients with heart failure on concomitant diuretic therapy. Frequently, these abnormalities resolved when the dosage of the diuretic was decreased.

Patients with acute myocardial infarction in the GISSI-3 trial treated with Zestril had a higher (2.4% versus 1.1% in placebo) incidence of renal dysfunction in-hospital and at six weeks (increasing creatinine concentration to over 3 mg/dL or a doubling or more of the baseline serum creatinine concentration).

(COX-2 Inhibitors)

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor [see Contraindications (4)]. ACE inhibitors have been associated with a higher rate of angioedema in black than in non-black patients.

6.2 Post-marketing Experience

The following adverse reactions have been identified during post-approval use of Zestril that are not included in other sections of labeling. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Other reactions include:

Metabolism and nutrition disorders nia [see Warnings and Precautions (5.4)], cases of hypoglycemia in diabetic patients on oral antidiabetic agents or insulin [see Drug Interactions (7.2)]

Nervous system and psychiatric disorders

Mood alterations (including depressive symptoms), mental confusion, hallucinations

Skin and subcutaneous tissue disorders

DRUG INTERACTIONS

7.1

Psoriasis

Diverties ion of Zestril in patients on divertics may result in excessive reduction of blood pressure. The possibility of hypot effects with Zestril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Zestril. If this is not possible, reduce the starting dose of Zestril [see Dosage and Administration (2.2) and Warnings and Precautions (5.4)].

Zestril attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated,

monitor the patient's serum potassium frequently

7.2 Antidiahetics

Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia.

7.3 Non-Steroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diurelic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.

The antihypertensive effect of ACE inhibitors, including lisinopril, may be attenuated by NSAIDs.

7.4 Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy

The VA NEPHRON trial enrolled 1,448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 mL/min to 89.9 mL/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years. Patients receiving the combination of losartan and lisinopril di not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group.

In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Zestril and other agents that affect the RAS.

Do not co-administer aliskiren with Zestril in patients with diabetes. Avoid use of aliskiren with Zestril in patients with renal ent (GFR <60 mL/min

7.5 Lithium

Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs, which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. Monitor serum lithium levels during concurrent use.

7.6 Gold

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including Zestril. mTOR Inhibitors

7.7

ents taking concomitant mTOR inhibitor (e.g. temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema. [see Warnings and Precautions (5.2)]

Neprilysin Inhibitor 7.8

ents taking concomitant neprilysin inhibitors may be at increased risk for angioedema. [see Warnings and Precautions (5.2)] USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Sumn

Zestril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue Zestril as soon as possible.

The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the general U.S. population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embrvo/fetal risk

Appendencion in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored end expressed experiments. and managed accordingly.

Fetal/Neonatal Adverse Reactions

Oligohydrawniais in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia and skeletal deformations, including skull hypoplasia, hypotension, and death. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.

Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, ba Perform serial bitrasound examinations to assess the initia-annuous environment, retail testing thay be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of *in utero* exposure to Zestril for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occur in neonates with a history of *in utero* exposure to Zestril, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypote and substituting for disordered renal function.

8.2 Lactation Risk Summary

No data are available regarding the presence of lisinopril in human milk or the effects of lisinopril on the breastfed infant or on milk production. Lisinopril is present in rat milk. Because of the potential for severe adverse reactions in the breastfed infant, advise women not to breastfeed during treatment with Zestril.

8.4 Pediatric Use

Antihypertensive effects and safety of Zestril have been established in pediatric patients aged 6 to 16 years [see Dosage and Administration (2.1) and Clinical Studies (14.1)]. No relevant differences between the adverse reaction profile for pediatric patients and adult patients were identified.

Safety and effectiveness of Zestril have not been established in pediatric patients under the age 6 or in pediatric patients with glomerular filtration rate < 30 mL/min/1.73 m² [see Dosage and Administration (2.1), Clinical Pharmacology (12.3), and *Clinical Studies* (14,1)1.

<u>Neonates with a history of *in utero* exposure to Zestril.</u> If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.

8.5 Geriatric Use

No dosage adjustment with Zestril is necessary in elderly patients. In a clinical study of Zestril in patients with myocardial infarctions (GISSI-3 Trial) 4.413 (47%) were 65 and over, while 1,656 (18%) were 75 and over. In this study, 4.8 % of patients aged 75 years and older discontinued Zestril treatment because of renal dysfunction vs. 1.3% of patients younger than 75 years. No other differences in safety or effectiveness were observed between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

8.6 Race

ACE inhibitors, including Zestril, have an effect on blood pressure that is less in black patients than in non blacks. 8.7 Renal Impairment


OVERDOSAGE

ving a single oral dose of 20 g/kg no lethality occurred in rats, and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Lisinopril can be removed by hemodialysis [see Clinical Pharmacology (12.3)].

11 DESCRIPTION

Lisinopril is an oral long-acting angiotensin converting enzyme (ACE) inhibitor. Lisinopril, a synthetic peptide derivative. is chemically described as (S)-1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-L-proline dihydrate. Its empirical formula is Ca.Ha.NaO.2HaO and its structural formula is



Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.53. It is soluble in water and sparingly soluble in methanol and practically insoluble in ethanol.

Zestril is supplied as 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg tablets for oral administration

Inactive Ingredients

2.5 mg tablets - calcium phosphate, magnesium stearate, mannitol, starch. mg, 10 mg, 20 mg and 30 mg tablets - calcium phosphate, magnesium stearate, mannitol, red ferric oxide, starch. 40 mg tablets - calcium phosphate, magnesium stearate, mannitol, starch, vellow ferric oxide,

CLINICAL PHARMACOLOGY 12 12.1

12.1 Mechanism of Action Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin-towering enzyme (ACC) mitunal subjects and animatics angiotensin II. Angiotensin I experime (ACC) mitunal subjects and animatics angiotensin II. Angiotensin I and the adversarial to the vaso constrictor substance, angiotensin II. Angiotensin I and best subjects and animatics angiotensin II and the adversarial cortex. The beneficial effects of lisinopril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasopressor activity and to decrease aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with Zestril alone for up to 24 weeks, the mean increase in serum potassium was approximately 0.1 mEq/L; however, approximately 15% of existing the adversaries greater than 0.5 mEq/L and approximately 6% of decreased greater than 0.5 mEq/L and approximately 6%. approximately 15% of patients had increases greater than 0.5 mEg/L and approximately 6% had a decrease greater than approximately in the same study, patients treated with Zestril and hydrochlorothiazide for up to 24 weeks had a mean decrease in serum potassium of 0.1 mEq/L; approximately 4% of patients had increases greater than 0.5 mEq/L and approximately 12% had a decrease greater than 0.5 mEq/L see *Clinical Studies (14.1)*]. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.

ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of Zestril remains to be elucidated

While the mechanism through which Zestril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, Zestril is antihypertensive even in patients with low-renin hypertension. Although Zestril was antihypertensive in all races studied, Black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to monotherapy than non Black patients.

Concomitant administration of Zestril and hydrochlorothiazide further reduced blood pressure in Black and non-Black patients and any racial differences in blood pressure response were no longer evident.

12.2 Pharmacodynamics

Adult Patients: Administration of Zestril to patients with hypertension results in a reduction of both supine and standing blood pressure to about the same extent with no compensatory tachycardia. Symptomatic postural hypotension is usually not observed although it can occur and should be anticipated in volume and/or salt-depleted patients *[see Warnings and Precautions (5.4)]*. When given together with thiazide-type diuretics, the blood pressure lowering effects of the two drugs are approximately additive

In most patients studied, onset of antihypertensive activity was seen at one hour after oral administration of an individual does of Zestril, with peak reduction of blood pressure achieved by 6 hours. Although an antihypertensive effect was observed 24 hours after dosing with recommended single daily doses, the effect was more consistent and the mean effect was considerably larger in some studies with doses of 20 mg or more than with lower doses; however, at all doses studied, the mean antihypertensive effect was substantially smaller 24 hours after dosing than it was 6 hours after dosing

The antihypertensive effects of Zestril are maintained during long-term therapy. Abrupt withdrawal of Zestril has not been associated with a rapid increase in blood pressure, or a significant increase in blood pressure compared to pretreatment levels. Non-Steroidal Anti-Inflammatory Agents

In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of Zestril alone were action of Zestril given concomitantly with indomethacin, the use of indomethacin was associated with a reduced effect, although the difference between the two regimens was not significant.

12.3 Pharmacokinetics

Adult Patients: Following oral administration of Zestril, peak serum concentrations of lisinopril occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Food does not alter the bioavailability of Zestril. Declining serum concentrations exhibit a prolonged termi phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to A and is not proportional to dose. Upon multiple dosing, lisinopril exhibits an effective half-life of 12 hours. ing to ACF

Lisinopril does not appear to be bound to other serum proteins. Lisinopril does not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25%, with large intersubject variability (6% to 60%) at all doses tested (5 mg to 80 mg). The absolute bioavailability of lisinopril is reduced to 16% in patients with stable NYHA Class I-IV congestive heart failure and the volume of distribution appears to be slightly smaller than that in normal subjects. The oral bioavailability of lisinopril in patients with acute myocardial infarction is similar to that in healthy volunteers.

Impaired renal function decreases elimination of lisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below 30 mL/min. Above this glomerular filtration rate, the elimination half-life is little changed. With greater impairment, however, peak and trough lisinopril levels increases, time to peak concentration increases and time to attain steady state is prolonged [see Dosage and Administration (AdV)]. (2.4)]. Lisinopril can be removed by hemodialysis.

Pediatric Patients: The pharmacokinetics of lisinopril were studied in 29 pediatric hypertensive patients between 6 years and To be and a dense in the pharmaconnected on manipul were studied in 25 penaltic hyper leaves platents between 0 years and 16 years with glomerular filtration rate > 30 mL/min.73 m². After doses of 0.1 mg per kg to 0.2 mg per kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours and the extent of abscription based on urinary recovery was about 28%. These values are similar to those obtained previously in adults. The typical value of lisinopril oral clearance (systemic clearance/absolute bioavailability) in a child weighing 30 kg is 10 L/h, which increases in proportion to renal inction. In a multicenter, open-label pharmacokinetic study of daily oral lisinopril in 22 pediatric hyper ensive patients with stable kidney transplant (ages 7 to 17 years; estimated glomerular filtration rate > 30 mL/min/1.73 m²), dose normalized exposures were in the range reported previously in children without a kidney transplant.

NONCLINICAL TOXICOLOGY 13 13.1

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility There was no evidence of a tumorigenic effect when lisinopril was administered for 105 weeks to male and female rats at doses up to 90 mg per kg per day (about 56 or 9 times" the maximum recommended daily human dose, based on body weight and body surface area, respectively). There was no evidence of carcinogenicity when lisinopril was administered for 92 weeks to (male and female) mice at doses up to 135 mg per kg per day (about 84 times" the maximum recommended daily human dose). This dose was 6.8 times the maximum human dose based on body surface area in mice.

Lisinopril was not mutagenic in the Ames microbial mutagen test with or without metabolic activation. It was also negative Lisinopril vas het indagene in de Anes interobal indagen est with of winder neutone autwatch, it was also negative in a forward mutation assay using Chinese hamster lung cells. Lisinopril did not produce single strand DNA breaks in an *in vitro* alkaline elution rat hepatocyte assay. In addition, lisinopril did not produce increases in chromosomal aberrations in an *in vitro* test in Chinese hamster ovary cells or in an *in vivo* study in mouse bone marrow.

There were no adverse effects on reproductive performance in male and female rats treated with up to 300 mg per kg per day of lisinopril. This dose is 188 times and 30 times the maximum human dose when based on mo/kn and mo/kn

Studies in rats indicate that lisinopril crosses the blood brain barrier poorly. Multiple doses of lisinopril in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of ¹⁴C lisinopril. By whole body autoradiography, radioactivity was found in the placenta following administration of labeled drug to pregnan rats, but none was found in the fetuses.

*Calculations assume a human weight of 50 kg and human body surface area of 1.62m²

CLINICAL STUDIES

14.1 Hypertension In controlled clinical studies of patients with mild to moderate hypertension, patients were treated with Zestril 20 mg to 80 mg daily, hydrochlorothiazide 12.5 mg to 50 mg daily or atenolol 50 mg to 200 mg daily; and in other studies of patients with moderate to severe hypertension, patients were treated with Zestril 20 mg to 80 mg daily or metoprolol 100 mg to 200 mg daily. Zestril demonstrated superior reductions of systolic and diastolic compared to hydrochlorothiazide in a population that was 75% Caucasian. Zestril was approximately equivalent to atenolol and metoproiol in reducing diastolic od pressure, and had somewhat greater effects on systolic blood pressure.

Zestril had similar blood pressure reductions and adverse effects in younger and older (> 65 years) patients. It was less effective in reducing blood pressure in Blacks than in Caucasians.

In hemodynamic studies of Zestril in natients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with little or no change in cardiac output and in heart rate. In a study in nine hypertensive patients, following administration of Zestril, there was an increase in mean renal blood flow that was not significant. Data from several small studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not large.

In patients with renovascular hypertension Zestril has been shown to be well tolerated and effective in reducing blood pressure [see Warnings and Precautions (5.3)]

Pediatric Patients: In a clinical study involving 115 hypertensive pediatric patients 6 to 16 years of age, patients who reutative rations. In a clinical study involving 115 hypertensive pleating patients of the years of age, platents who weighed < 50 kg received either 0.625 mg, 2.5 mg or 20 mg of Zestril once daily and patients who weighed < 50 kg received either 0.625 mg, 5 mg, or 40 mg of Zestril once daily. At the end of 2 weeks, Zestril lowered trough blood pressure in a dose-dependent manner with antihypertensive efficacy demonstrated at doses > 1.25 mg (0.02 mg per kg). This effect was confirmed in a randomized withdrawal phase, where the diastolic pressure rose by about 9 mmHg more in patients who remained on the middle and high doses of lisinopril. The dose-dependent and the processing effort of 2 received to placebo than compared to patients who remained on the middle and high doses of lisinopril. The dose-dependent effbaced forces are observed domegorable outpressure areas the processing of the days of the days of the processing of the days of the processing of the days of the dependent antihypertensive effect of Zestril was consistent across several demographic subgroups; age. Tanner stage gender, and race. In this study, lisinopril was generally well-tolerated.

In the above pediatric studies, Zestril was given either as tablets or in a suspension for those children and infants who were unable to swallow tablets or who required a lower dose than is available in tablet form [see Dosage and Administration (2.1)].

14.2 Heart Failure

In two placebo controlled, 12-week clinical studies compared the addition of Zestril up to 20 mg daily to digitalis and In two placebo controlled, 12-week clinical studies compared the addition of zestin up to zo ing dairy to uguans and diuretics alone. The combination of Zestril, digitalis and diuretics reduced the following signs and symptoms of heart failure: edema, rales, paroxysmal nocturnal dyspnea and jugular venous distention. In one of the studies, the combination of Zestril, digitalis and diuretics reduced orthopnea, presence of third heart sound and the number of patients classified as NYHA Class III and IV; and improved exercise tolerance. A large (over 3,000 patients) survival study, the ATLAS Trial, exercise to the part of the provide studies with excitate heart failure, showed that the higher does of lisionori comparing 2.5 mg and 35 mg of lisinopril in patients with systolic heart failure, showed that the higher dose of lisinopril had outcomes at least as favorable as the lower dose.

During baseline-controlled clinical trials, in patients with systolic heart failure receiving digitalis and diuretics, single doses of Zestril resulted in decreases in pulmonary capillary wedge pressure, systemic vascular resistance and blood pressure accompanied by an increase in cardiac output and no change in heart rate.

14.3 Acute Myocardial Infarction

The Gruppo Italiano per lo Studio della Sopravvienza nell'Infarto Miocardico (GISSI-3) study was a multicenter, controlled, randomized, unblinded clinical trial conducted in 19,394 patients with acute myocardial infarction (MI) admitted to a coronary care unit. It was designed to examine the effects of short-term (6 week) treatment with lisinopril, nitrates, their combinations of the effects of short-term (6 week) treatment with lisinopril, nitrates, their combinations of the effects of short-term (6 week) treatment with lisinopril, nitrates, their combinations of the effects of short-term (6 week) treatment with lisinopril, nitrates, their combinations of the effects of short-term (6 week) treatment with lisinopril, nitrates, their combinations of the effects of short-term (6 week) treatment with lisinopril, nitrates the field of the effects of short-term (6 week) treatment with lisinopril, nitrates the field of the effects of short-term (6 week) treatment with lisinopril, nitrates the field of the short of the effects of short-term (6 week) treatment with lisinopril, nitrates the field of the effects of short-term (6 week) treatment with lisinopril, nitrates the field of the effects of short-term (6 week) treatment with lisinopril, nitrates the short (6 week) treatment with lisinopril, nitrates the field of the effects of short-term (6 week) treatment with lisinopril, nitrates the field of combination, or no therapy on short-term (6 week) mortality and on long-term death and markedly impaired cardiac function. Hemodynamically- stable patients presenting within 24 hours of the onset of symptoms were randomized, in a 2×2 factorial design, to six weeks of either 1) Zestril alone (n=4841), 2) nitrates alone (n=4869), 3) Zestril plus nitrates (n=4841), c + 4) open control (n=4843). All patients received routine therapies, including thrombotytics (72%), asprin (84%), and a beta blocker (31%), as appropriate, normally utilized in acute myocardial infarction (MI) patients.

The protocol excluded patients with hypotension (systolic blood pressure ≤ 100 mmHg), severe heart failure, cardiogenic shock, and renal dysfunction (serum creatinine > 2 mg per dL and/or proteinuria > 500 mg per 24 h). Patients randomized to Zestril received 5 mg within 24 hours of the onset of symptoms, 5 mg after 24 hours, and then 10 mg daily thereafter. Patients with systolic blood pressure less than 120 mmHg at baseline received 2.5 mg of Zestril. If hypotension occurred, the Zestril dose was reduced or if severe hypotension occurred Zestril was stopped [see Dosage and Administration (2.3)].

The primary outcomes of the trial were the overall mortality at 6 weeks and a combined end point at 6 months after the myocardial infarction, consisting of the number of patients who died, had late (day 4) clinical congestive heart failure, or had myocardial infraction, consisting of the number of patients who died, had late (day 4) clinical congestive heart failure, or had extensive left ventricular damage defined as ejection fraction < 35% or an akinetic-dyskinetic [A-D] score < 45%. Patients receiving Zestril (n=9646), alone or with nitrates, had an 11% lower risk of death (p=0.04) compared to patients who did not receive Zestril (n=9672) (6.4% vs. 7.2%, respectively) at six weeks. Although patients randomized to receive Zestril for up to six weeks also fared numerically better on the combined end point at 6 months, the open nature of the assessment of heart failure, substantial loss to follow-up echocardiography, and substantial excess use of Zestril between 6 weeks and 6 months in the group randomized to 6 weeks of lisinopril, preclude any conclusion about this end point.

Patients with acute myocardial infarction, treated with Zestril, had a higher (9.0% versus 3.7%) incidence of persistent hypotension (systolic blood pressure < 90 mmHg for more than 1 hour) and renal dysfunction (2.4% versus 1.1%) in-hospital and at six weeks (increasing creatinine concentration to over 3 mg per dL or a doubling or more of the baseline serum creatinine concentration) [see Adverse Reactions (6.1)].

16 HOW SUPPLIED/STORAGE AND HANDLING

Zestri is available as uncoated biconvex tablets in bottles of 90.											
Strength	Color	Shape	Scored	Side 1/Side 2	Bottle Count	NDC 52427-					
2.5 mg	White	Round	No	ZESTRIL 2½/135	90 Tablets	438-90					
5 mg	Pink	Capsule-Shaped	Yes	ZESTRIL/130	90 Tablets	439-90					
10 mg	Pink	Round	No	ZESTRIL 10/131	90 Tablets	440-90					
20 mg	Pale Brownish Red	Round	No	ZESTRIL 20/132	90 Tablets	441-90					

Store at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. Protect from moisture, freezing and excessive heat. Dispense in a tight container.

Pregnancy: Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females

of reproductive potential to notify their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].

Angioedema: Angioedema, including laryngeal edema may occur at any time during treatment with angiotensin converting enzyme inhibitors, including Zestril. Tell patients to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they

Symptomatic Hypotension: Tell patients to report light-headedness especially during the first few days of therapy. If actual

Tell patients that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood

Hypoglycemia: Tell diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor to monitor for

Leukopenia/Neutropenia: Tell patients to report promptly any indication of infection (e.g., sore throat, fever), which may be

Lactation: Advise women not to breastfeed during treatment with Zestril [see Use in Specific Populations (8.2)].

syncope occurs, tell the patient to discontinue the drug until they have consulted with the prescribing physicial

Hyperkalemia: Tell patients not to use salt substitutes containing potassium without consulting their physician

hypoglycaemia closely, especially during the first month of combined use [see Drug Interactions (7.2)].

No

No

Round

Round

ZESTRIL 30/133

ZESTRIL 40/134

442-90

443-90

90 Tablets

90 Tablets

NOTE: This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

have consulted with the prescribing physician.

pressure; advise patients accordingly.

Zestril is a registered trademark of Alvogen AZ IP Holdings LLC.

a sign of leukopenia/neutrop

Distributed by: Almatica Pharma LLC Morristown, NJ 07960 USA

PI438-11

Rev. 03/2020

Pale Brownish Red

Yellow

30 mg

40 mg

'estril is No dose adjustment of Zestril is required in patients with creatinine clearance > 30 mL/min [see Dosage and Administration] (2.4) and Clinical Pharmacology (12.3)].

Two dose-response studies utilizing a once-daily regimen were conducted in 438 mild to moderate hypertensive patients not on a diuretic. Blood pressure was measured 24 hours after dosing. An antihypertensive effect of Zestril was seen with 5 mg of Zestril in some patients. However, in both studies blood pressure reduction occurred sooner and was greater in patients watch utility down 20 mer a 00 mer of Castril theorem of the theorem of Castril. treated with 10 mg, 20 mg or 80 mg of Zestril than patients treated with 5 mg of Zestril.